Revision History
2 revisions for "The Addiction Breakthrough Hiding Inside Your Weight-Loss Drug: How GLP-1 Medications Are Rewriting the Rules of Substance Use Treatment"
A landmark study of more than 600,000 U.S. veterans — the largest of its kind — has found that GLP-1 receptor agonists like Ozempic are associated with significantly lower risks of developing substance use disorders across every major addictive substance and a 50% reduction in drug-related deaths among those already struggling with addiction. With more than 15 clinical trials now underway globally, the question has shifted from whether these drugs affect addiction to when they might be approved for treatment — even as critical questions about equity, long-term effects, and the gap between correlation and causation remain unresolved.
A landmark study of over 600,000 U.S. veterans has found that GLP-1 receptor agonists — the same drugs behind the Ozempic and Wegovy weight-loss phenomenon — are associated with dramatically lower risks of substance use disorders across every major addictive substance, including a 50% reduction in drug-related deaths among those already struggling with addiction. While the findings have electrified the addiction research community and sent media coverage surging, experts caution that randomized clinical trials are still needed before these medications can be prescribed for addiction, and critical questions remain about long-term effects, tolerance, and what happens when patients stop taking the drugs.